2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(E)-pyridin-4-ylmethylidene]acetohydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(E)-pyridin-4-ylmethylidene]acetohydrazide
• 英文别名: 2-(1H-benzimidazol-2-ylsulfanyl)-N-[(E)-pyridin-4-ylmethylideneamino]acetamide
• 化学式: C₁₅H₁₃N₅OS
• 分子量: 311.4
• InChiKey: NFZHWZFMXUIYCX-RQZCQDPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOSITIONS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED
  申请人：Brandeis University

  公开号：EP3085367A2

  公开（公告）日：2016-10-26

  One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-1 Trp32, including molecules that bind in a site adjacent to SOD-1 Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.

  本发明的一个方面涉及一种治疗或预防神经退行性疾病的方法，包括向有需要的患者施用治疗有效量的高级糖化终产物形成抑制剂。本发明的另一个方面涉及一种基于蛋白酶体活性的筛选试验，用于选择可能有助于治疗或预防神经退行性疾病的化合物及其所用材料。本发明的另一个方面涉及在SOD-1 Trp32处或其邻近部位结合的分子及其使用方法，包括在SOD-1 Trp32邻近部位结合的分子，无论其是否被氧化，用于治疗或预防神经退行性疾病。
• COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES
  申请人：Brandeis University

  公开号：EP2139460A1

  公开（公告）日：2010-01-06
• Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases
  申请人：Agar Jeffrey N.

  公开号：US20100152125A1

  公开（公告）日：2010-06-17

  One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.
• US8609649B2
  申请人：——

  公开号：US8609649B2

  公开（公告）日：2013-12-17
• [EN] COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT, AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS PERMETTANT LE DIAGNOSTIC, LE TRAITEMENT ET LA PRÉVENTION DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE ET DES MALADIES NEUROLOGIQUES APPARENTÉES
  申请人：UNIV BRANDEIS

  公开号：WO2008116092A1

  公开（公告）日：2008-09-25

  [EN] One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.
  [FR] L'invention concerne, dans un aspect, un procédé de traitement ou de prévention d'une maladie neurodégénérative, comprenant l'étape d'administration à un patient qui en a besoin, d'une quantité thérapeutiquement efficace d'un inhibiteur de la formation de produits finaux de glycation avancés. Un autre aspect de l'invention concerne un dosage de criblage à base d'activité de protéasome pour sélectionner des composés qui peuvent être utiles pour traiter ou prévenir une maladie neurodégénérative, et des matériaux utilisés dans celui-ci. Encore un autre aspect de l'invention concerne des molécules, et des procédés d'utilisation de celles-ci, qui se lient à SOD-I Trp32, ou se lient près de celui-ci, y compris les molécules qui se lient dans un site près de SOD-I Trp32, qui sont oxydées ou non, pour traiter ou prévenir une maladie neurodégénérative.